Key Takeaways:
Karyopharm Therapeutics’ Phase 3 myelofibrosis drug data has been accepted for a late-breaking oral presentation at the 2026 ASCO annual meeting.
The presentation will feature results from the SENTRY trial and will be delivered by Dr. John Mascarenhas, a Professor of Medicine at the Icahn School of Medicine at Mount Sinai, the company said in a statement.
The Phase 3 SENTRY study evaluated a once-weekly 60 mg dose of selinexor combined with ruxolitinib against a placebo plus ruxolitinib in patients new to JAK inhibitor treatment. The trial's co-primary endpoints are a spleen volume reduction of at least 35% at week 24 and the average change in total symptom score over the same period.
The acceptance for a late-breaking presentation suggests the data may be clinically significant, a potentially major catalyst for Karyopharm as it seeks to enter the front-line treatment setting for a disease affecting approximately 20,000 patients in the United States.
Myelofibrosis is a rare blood cancer that causes scarring in the bone marrow, leading to an enlarged spleen, anemia, and severe symptoms. The only approved therapies for the disease are JAK inhibitors, with ruxolitinib being the established standard of care. Karyopharm’s selinexor, an oral XPO1 inhibitor marketed as XPOVIO for other cancers, aims to improve outcomes when added to this standard.
The ASCO abstract and full presentation will be released on the morning of June 2. The event will also feature data from other companies in the space, including an oral presentation from Disc Medicine on its Phase 2 RALLY-MF trial for DISC-0974 in anemic myelofibrosis patients, making the session a key focus for hematology investors.
A positive outcome in the SENTRY trial would be a significant validation for Karyopharm’s pipeline and could position selinexor as a new standard-of-care component in the first-line setting. Investors will be closely watching the full data release on June 2 for details on both efficacy and safety.
This article is for informational purposes only and does not constitute investment advice.
